All In Biotech

Drug Trial Radar · NCT07738055

Study on the Combined Treatment of Hepatocellular Carcinoma With Envafolimab, Suvemcitug and HAIC Conversion

An Exploratory Study on the Use of Envafolimab Combined With Suvemcitug and HAIC for the Conversion Therapy of Potentially Resectable Hepatocellular Carcinoma

Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

35

Planned (sponsor's estimate)

Start

Jul 31, 2026

Primary completion

Jan 31, 2029

Study completion Jul 31, 2029

Sponsor

Lead sponsor
Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a single-center, exploratory clinical trial. Eligible patients with liver cancer, after signing the informed consent form, will be screened and enrolled. They will receive a 3-cycle conversion treatment with Envafolimab combined with Suvemcitug and HAIC. During the treatment process, clinical tumor imaging assessment will be conducted using RECIST V1.1. Imaging evaluations will be performed before treatment and at the end of the 3rd cycle of treatment (±3 days). Subsequently, an MDT assessment will be conducted to determine if the surgical resection criteria are met. If the criteria are met, a radical surgery will be performed based on the subject's wishes and postoperative treatment will be provided. If the criteria are not met, the study will be decided to continue with the original treatment plan or another treatment plan. CTCAE 5.0 will be used for safety assessment. Adverse events will be recorded throughout the study period until 30 days after the end of treatment (for severe adverse events or adverse events related to Envovalimab, the recording period will be extended to 90 days after the end of treatment). To ensure study safety, 3 patients will be enrolled as a safety introduction cohort first, and a 3-cycle conversion treatment with Suvemcitug combined with Envafolimab and HAIC will be used. If a DLT occurs, 3 more patients will be enrolled. If the overall DLT does not exceed 1/3, the original treatment plan will be maintained for the study. If the overall DLT is greater than 1/3, the drug related to the DLT will be re-evaluated and the dose will be adjusted.

Conditions

  • Potentially Resectable Hepatocellular Carcinoma

Interventions

  • Envafolimab: 400mg, subcutaneous injection Suvemcitug: 2mg/kg, intravenous injection HAIC: Oxaliplatin 85mg/m² + 5-FU 2400-3200mg/m², continuous infusion, every 3 weeksDrug

    Suvemcitug is administered via intravenous infusion at a fixed dose of 2 mg/kg on Day 1 of every 21-day cycle (Q3W). Envafolimab is given by subcutaneous injection at a fixed dose of 400 mg on Day 1 of every 21-day cycle (Q3W). Concurrent Hepatic Artery Infusion Chemotherapy (HAIC) adopts standard FOLFOX regimen: Oxaliplatin 85 mg/m² administered via hepatic artery catheter, followed by continuous infusion of 5-Fluorouracil at a dose range of 2400-3200 mg/m², repeated every 3 weeks. This triple combination neoadjuvant conversion therapy will be administered for a maximum of 3 cycles to eligible patients with potentially resectable hepatocellular carcinoma (HCC) in this single-arm, single-center exploratory clinical trial. Tumor imaging assessments will be conducted in accordance with RECIST Version 1.1 at two specified time points: baseline before treatment initiation, and within ±3 days after completion of the 3rd treatment cycle. After finishing 3 cycles of combination therapy, a mul

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Surgical conversion rateTime frame: The conversion rate for the first to third cycles of medication (each cycle lasting 21 days)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.